This web site is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

INS37217 Intranasal

Merck & Co., Inc.

Drug Names(s): INS37217 Intranasal

Description: INS37217 is a P2Y2 receptor agonist for the treatment of upper respiratory disorders involving impaired clearance, including rhinosinusitis, allergic rhinitis, and common cold.

Deal Structure: INS37217 was originally developed by Inspire.

In April 2011, Merck and Inspire Pharmaceuticals announced that they have entered into a definitive agreement under which Merck will acquire Inspire. In May 2011, Merck announced that it is has completed its acquisition of Inspire Pharmaceuticals.


Additional information available to subscribers only:

  • Targets
  • Routes
  • Catalysts
  • Designations
  • Events

Request a Free Demo Subscriber Login Search for another drug